{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-068880","form_type":"8-K","ticker":null,"cik":"0001808158","company_name":"Repare Therapeutics Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.963174+00:00","generated_at":"2026-05-24T02:09:25.635431+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Repare Therapeutics CEO Segal resigns; CFO Steve Forte becomes CEO effective April 11","bullets":["Lloyd Segal resigns as President, CEO, and Director effective April 11, 2025; not due to disagreement.","Steve Forte (current EVP/CFO) appointed President, CEO, and Director effective same date; will remain CFO.","Sandra Alves promoted to SVP, Chief Accounting Officer; salary raised to CA$350,000; granted 24,500 options and 4,100 RSUs.","Company expects to complete MYTHIC trial enrollment Q2 2025; topline data for POLAR (Q3) and LIONS (Q4) trials.","Company exploring strategic alternatives and partnerships across portfolio, including for lunresertib and camonsertib."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-068880","json":"https://secwatch.observer/filing/0001193125-25-068880.json","markdown":"https://secwatch.observer/filing/0001193125-25-068880.md","text":"https://secwatch.observer/filing/0001193125-25-068880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525068880/0001193125-25-068880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525068880/d923441d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:09:25.635431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a01b74840","claim":"Steve Forte was appointed as President and Chief Executive Officer at Repare Therapeutics Inc..","evidence_excerpt":"the Board appointed Steve Forte to serve as the Company’s President and Chief Executive Officer in addition to his current role as the Company’s Chief Financial Officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525068880/0001193125-25-068880-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6eac7dd7a9","claim":"Lloyd Segal resigned as President and Chief Executive Officer at Repare Therapeutics Inc..","evidence_excerpt":"On March 31, 2025, Lloyd Segal, President and Chief Executive Officer of Repare Therapeutics Inc. (the “ Company ”), notified the board of directors (the “ Board ”) of the Company of his resignation from his positions as President and Chief Executive Officer and as a member of the Board, effective April 11, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525068880/0001193125-25-068880-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}